SANDOZ VORICONAZOLE 200 MG
VORICONAZOLE : 200 MG · DIN 02399253 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ VORICONAZOLE?
SANDOZ VORICONAZOLE 200 MG contains VORICONAZOLE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02399253, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Apr-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ VORICONAZOLE used for?
Invasive aspergillosis; Candidemia in non-neutropenic patients and specific Candida infections (disseminated skin, abdomen, kidney, bladder wall, and wounds).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02399253 |
|---|---|
| Brand name | SANDOZ VORICONAZOLE |
| Generic / active ingredient | VORICONAZOLE : 200 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J02AC03 VORICONAZOLE |
| AHFS class | 08:14.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Apr-2014 |
| Original market date | 2014-04-02 00:00:00 |
How is it administered?
Loading dose: 6 mg/kg IV or 400 mg oral BID (Day 1). Maintenance: 3-4 mg/kg IV BID or 200 mg oral BID. Oral tablets taken 1h before or 2h after meals. IV infused over 1-2 hours.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted IV solution: Use immediately or store up to 24 hours at 2°C to 8°C. (General storage not explicitly detailed in provided snippet).
How is it supplied?
Tablets: 50 mg and 200 mg. Injection: 200 mg/vial single-use sterile lyophile.
Contraindications
Hypersensitivity to voriconazole; coadministration with CYP3A4 substrates (e.g., quinidine, lurasidone, sirolimus, lovastatin) or inducers (e.g., rifampin, carbamazepine, St. John's Wort).
Warnings and precautions
Serious drug interactions; QT interval prolongation; Visual disturbances; Hepatic toxicity; Severe cutaneous adverse reactions (SCARs); Fluorosis/periostitis with long-term use.
Is VORICONAZOLE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J02AC03 VORICONAZOLE. 11 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP VORICONAZOLE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02525798 |
| JAMP VORICONAZOLE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02525771 |
| SANDOZ VORICONAZOLE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02399245 |
| VFEND | 200 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02256487 |
| VFEND | 200 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02256479 |
| VFEND | 200 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02279991 |
| VFEND | 50 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02256460 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02381966 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02477696 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02493829 |
Who else supplies VORICONAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VORICONAZOLE appears in 194 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.